We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RXST market cap is 1.36B. The company's latest EPS is USD -1.2060 and P/E is -27.91.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 22.2M | 28.58M | 29.51M | 34.89M | 35.31M |
| Operating Income | -12.51M | -10.85M | -10.67M | -8.33M | -9.23M |
| Net Income | -12.42M | -9.18M | -9.1M | -6.08M | -6.34M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.24M | 14.68M | 22.59M | 49.01M | 89.08M |
| Operating Income | -46.59M | -35.41M | -52.79M | -63.32M | -50.09M |
| Net Income | 126.22M | 27.58M | -48.69M | -66.76M | -48.61M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 181.85M | 182.55M | 183.17M | 305.5M | 310.47M |
| Total Liabilities | 20.37M | 22.19M | 19.24M | 30.29M | 33.21M |
| Total Equity | 161.48M | 160.36M | 163.93M | 275.21M | 277.26M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 110.43M | 100.68M | 192.72M | 150.16M | 182.55M |
| Total Liabilities | 87.46M | 44.91M | 54.48M | 60.26M | 22.19M |
| Total Equity | -419.81M | -430.59M | 138.24M | 89.9M | 160.36M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -33.29M | -41.59M | -9.31M | -13.34M | -12.69M |
| Investing | -26.7M | -22.13M | 24.27M | -91.37M | -100.63M |
| Financing | 57.96M | 61.52M | 7.99M | 119.47M | 120.34M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -40.62M | -35.2M | -44.71M | -58.85M | -41.59M |
| Investing | -5.87M | 15.59M | -81.91M | 39.95M | -22.13M |
| Financing | 1.33M | 25.24M | 137.34M | 6.33M | 61.52M |
| Market Cap | 1.36B |
| Price to Earnings Ratio | -27.91 |
| Price to Sales Ratio | 15.23 |
| Price to Cash Ratio | 139.96 |
| Price to Book Ratio | 8.46 |
| Dividend Yield | - |
| Shares Outstanding | 40.3M |
| Average Volume (1 week) | 810.21k |
| Average Volume (1 Month) | 755.54k |
| 52 Week Change | -13.59% |
| 52 Week High | 67.60 |
| 52 Week Low | 33.665 |
| Spread (Intraday) | 2.28 (6.37%) |
| Company Name | RxSight Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.rxsight.com |
| Industry | ophthalmic goods (3851) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
